宁波天益医疗器械股份有限公司 2025 年半年度报告全文 宁波天益医疗器械股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 宁波天益医疗器械股份有限公司 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 2025 年半年度报告 2025-042 2025 年 8 月 公司负责人吴志敏、主管会计工作负责人邵科杰及会计机构负责人(会计 主管人员)邵科杰声明：保证本半年度报告中财务报告的真实、准确、完整。 1 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | | 第二节 | 公司简介和主要财务指标 8 | | | --- | --- | --- | | 第三节 | 管理层讨论与分析 11 | | | 第四节 | 公司治理、环境和社会 43 | | | 第五节 | 重要事项 | 47 | | 第六节 | 股份变动及股东情况 | 55 | | 第七节 | 债券相关情况 | 61 | | 第八节 | 财务报告 | 62 | 宁波天益医疗器械股份有限公司 2025 年半年度报 ...

Group 1 - The latest stock price of Tianyi Medical is 47.38 yuan, an increase of 2.20% compared to the previous trading day [1] - The stock opened at 46.24 yuan, reached a high of 48.17 yuan, and a low of 45.64 yuan, with a trading volume of 7,191 hands and a transaction amount of 0.34 billion yuan [1] - Tianyi Medical's main business includes the research, production, and sales of medical devices, covering multiple medical fields such as extracorporeal circulation and blood purification equipment [1] Group 2 - The company has a complete industrial chain layout as a medical enterprise in the Zhejiang region [1] - On the day of reporting, the net outflow of main funds for Tianyi Medical was 665,600 yuan, with a cumulative net outflow of 12.48 million yuan over the past five trading days [1] - The current total market value of the company is 2.793 billion yuan, and the circulating market value is 869 million yuan [1]

Core Insights - The report highlights the significant role of CFOs in listed companies, with the total compensation for A-share CFOs reaching 4.27 billion yuan in 2024, averaging 814,800 yuan per year [1][2] Group 1: CFO Compensation Overview - The average annual salary for CFOs in the A-share medical device sector is 908,600 yuan [2] - The distribution of CFO salaries shows that 24% earn below 500,000 yuan, 42% earn between 500,000 and 1 million yuan, 29% earn between 1 million and 2 million yuan, and 5% earn above 2 million yuan [2] - The top three highest-paid CFOs are Dai Zhenhua from Huatai Medical at 2.70 million yuan, Rui Chenwei from Nanwei Medical at 2.65 million yuan, and Wu Jinhong from Guoke Hengtai at 1.77 million yuan [2] Group 2: CFO Demographics - The age distribution of CFOs shows that those aged 40-50 make up 57%, while 32% are over 50, and 11% are 40 or younger [1] - The youngest CFO is 31 years old, while the oldest is 60 years old [1] - In terms of educational background, 16% of CFOs have an associate degree, 66% hold a bachelor's degree, 16% have a master's degree, and only 2% possess a doctoral degree [1] Group 3: Salary Changes - Among CFOs with over two years of tenure, the largest salary decrease was observed for Kong Xiangqian from Aidi Te, with a decline of 16.86% year-on-year [2] - Conversely, the largest salary increase was for Song Yizhao from Shandong Glass, with a rise of 144.86% year-on-year [2]

Group 1 - Beijing Tianyi Medical Equipment Co., Ltd. has been established with a registered capital of 10 million yuan [1] - The company is involved in the production and sales of various medical devices, including Class I and Class II medical devices, as well as non-medical masks [1] - The business scope also includes manufacturing and sales of plastic and rubber products, metal products, general equipment, and chemical products [1] Group 2 - The company is fully owned by Tianyi Medical, indicating a centralized ownership structure [1] - The company is permitted to engage in the production and sales of Class II and Class III medical devices, as well as disinfection equipment, subject to regulatory approval [1] - The operational activities are conducted in accordance with the business license and relevant regulatory approvals [1]

Core Viewpoint - The medical device industry experienced a slight increase of 0.47% on July 28, with a net outflow of funds amounting to 295 million [1] Group 1: Market Performance - A total of 52 stocks in the sector rose, while 68 stocks declined [1] - The top-performing stocks included: - Aidi Te (16.88%) - Kehua Bio (10.01%) - Rejing Bio (6.88%) - Zhengchuan Co. (6.68%) - David Medical (6.55%) [1][1][1] Group 2: Fund Flow - The net capital flow for the top gainers was as follows: - Aidi Te: 106 million - Kehua Bio: 12 million - Rejing Bio: 21 million - Zhengchuan Co.: -14 million (outflow) [1][1][1] - Other notable stocks with positive fund flow included: - David Medical: -6 million (outflow) - Sainuo Medical: 6 million [1][1] Group 3: Declining Stocks - The stocks with the largest declines included: - Aohua Endoscopy (-4.09%) - Tianyi Medical (-2.73%) - Mountain Outside Mountain (-2.53%) - Ruimaite (-2.42%) - Jianfan Bio (-2.32%) [1][1][1] - Additional stocks that saw declines were: - Lude Medical (-2.22%) - Nanwei Medical (-2.14%) - San Nuo Bio (-2.13%) [1][1]

Summary of Key Points Core Viewpoint - Tianyi Medical (301097) has shown a significant increase in stock price, closing at 48.4 yuan on July 25, 2025, with a rise of 4.85% [1] Financial Performance - The company reported a main revenue of 98.51 million yuan in Q1 2025, reflecting a year-on-year increase of 1.65% [5] - The net profit attributable to shareholders was 4.88 million yuan, a decrease of 9.81% year-on-year [5] - The company experienced a negative non-recurring net profit of -520,700 yuan, down 123.38% year-on-year [5] - The gross profit margin stood at 33.25% [5] Market Activity - On July 25, 2025, the net inflow of main funds was 4.05 million yuan, accounting for 2.98% of the total transaction amount [1][2] - Retail investors contributed a net inflow of 3.07 million yuan, representing 2.26% of the total transaction amount [1][2] - The stock had a turnover rate of 15.33% on the same day, with a total transaction volume of 28,100 hands and a transaction amount of 136 million yuan [1] Financing and Margin Trading - On July 25, 2025, the financing balance was 39.70 million yuan, with a net financing purchase of 1.70 million yuan [3] - There were no shares sold or repaid in the margin trading segment, indicating no activity in this area [3] Industry Comparison - Tianyi Medical's total market value is 2.853 billion yuan, significantly lower than the industry average of 11.518 billion yuan [5] - The company's net asset value is 1.194 billion yuan, compared to the industry average of 3.919 billion yuan [5] - The price-to-earnings ratio (P/E) is 146.28, which is considerably higher than the industry average of 63.28 [5] - The net profit margin of 4.95% is below the industry average of 10.86% [5]

Group 1 - Tianyi Medical (301097) closed at 42.92 yuan on July 18, 2025, with an increase of 1.11% and a turnover rate of 6.02% [1] - The trading volume was 11,000 shares, with a total transaction amount of 47.0881 million yuan [1] - On the same day, the net inflow of main funds was 3.7363 million yuan, while the net outflow of speculative funds and retail investors was 2.8381 million yuan and 0.8982 million yuan, respectively [2][4] Group 2 - Tianyi Medical announced a change in the use of raised funds, terminating the "Comprehensive R&D Center Construction Project" of its subsidiary, Ningbo Tairis Technology Co., Ltd., and reallocating the remaining and over-raised funds to the "Thailand Production Base Construction Project" [2] - This change was approved by the shareholders' meeting on January 13, 2025, and the company has opened a special account for the raised funds at China Industrial Bank (Thailand) [2] - A five-party supervision agreement was signed to regulate the management of the raised funds, ensuring they are used solely for the "Thailand Production Base Construction Project" [3][4]

Core Viewpoint - Ningbo Tianyi Medical Instrument Co., Ltd. has announced the establishment of a special account for raised funds and signed a five-party supervision agreement for the management of these funds, shifting the focus from a previously planned project to a new project in Thailand [1][2]. Fundraising Basic Information - The company raised a total of 14736800 shares at an issuance price of RMB 52.37 per share, resulting in total fundraising of approximately RMB 772.5 million. After deducting related expenses of RMB 18.04 million, the net amount raised is RMB 694.56 million [1][2]. Changes in Fund Usage - The company has decided to terminate the original fundraising project for the "Comprehensive R&D Center Construction Project" and redirect all remaining funds to the new "Thailand Production Base Construction Project" [1][2]. Establishment of Special Fund Account - A special account for the raised funds has been established at the Industrial and Commercial Bank of China (Thailand) with the account number 5100303754, specifically for the Thailand production base project [2][3]. Five-Party Supervision Agreement - The five-party supervision agreement includes the company, its Singapore subsidiary, its Thai subsidiary, the Industrial and Commercial Bank of China (Thailand), and the sponsor, Guotai Junan Securities. This agreement aims to regulate the management of the raised funds and protect the rights of small investors [5][6]. Fund Transfer Process - The process for transferring the remaining funds involves several steps, including returning funds from the subsidiary to the company and then transferring them to newly established accounts for both RMB and USD at the Shanghai Pudong Development Bank [2][4]. Completion of Fund Management Steps - The company has completed the necessary steps for fund management, including the reduction of capital for its subsidiary and the establishment of both RMB and USD special accounts at the Shanghai Pudong Development Bank [3][4].

证券代码：301097 证券简称：天益医疗 公告编号：2025-039 宁波天益医疗器械股份有限公司 关于开立募集资金专项账户 并签署募集资金五方监管协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 宁波天益医疗器械股份有限公司（以下简称"天益医疗"或"公司"）于 2024 年 12 月 27 日召开第三届董事会第二十次会议、第三届监事会第十七次会议审议 通过了《关于变更募集资金用途的议案》，同意变更募集资金用途，同意终止原 计划由子公司宁波泰瑞斯科技有限公司实施的募投项目"综合研发中心建设项 目"，并将其剩余全部募集资金变更用于新项目"泰国生产基地建设项目"；同 时同意将剩余超募资金全部调整用于"泰国生产基地建设项目"。本次变更事项 已经公司于 2025 年 1 月 13 日召开的 2025 年第一次临时股东大会审议通过。 截至本公告披露日，公司已完成在中国工商银行（泰国）股份有限公司募集 资金专项账户的开立及募集资金五方监管协议的签署，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意宁波天益医疗器械股份有限公司首 次公开 ...

Group 1 - The A-share medical device sector experienced a short-term surge, with Baolait rising over 17% [1] - Other stocks such as Jinan Development, Yangpu Medical, Tianyi Medical, Diri Medical, Guanhao Biological, and Chunli Medical also saw increases [1] - The rise in stock prices is attributed to the Chinese government's procurement measures affecting medical devices imported from the European Union [1]